Charles C. Liu
Research Subjects
Charles C. Liu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ron Xiaolong Yu
Department of Biostatistics, Gilead Sciences
5 shared publications- Bing Shao
China Agricultural University
1 shared publication Grant T. Hopkins
Department of Biostatistics, The University of Washington
1 shared publication- Jing Zhang
Key Laboratory of Groundwater Sciences and Engineering
1 shared publication Jingfu Liu
State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, P.O. Box 2871, Beijing 100085, China
1 shared publication- Liping Liu
Chronic Disease Research Center
1 shared publication
Latest Publications
- 20 June 2025
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 18 (1) , 97-105
Empirical Comparison of Five Parametric Curves in Fifty Dose–Response Studies
- 20 June 2025
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 18 (1) , 97-105
Empirical Comparison of Five Parametric Curves in Fifty Dose–Response Studies
- 6 September 2024
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 58 (6) , 1180-1189
Delta Inflation, Optimism Bias, and Uncertainty in Clinical Trials
The phenomenon of delta inflation, in which design treatment effects tend to exceed observed treatment effects, has been documented in several therapeutic areas. Delta inflation has often been attributed to investigators’ optimism bias, or an unwarranted belief in the efficacy of new treatments. In contrast, we argue that delta inflation may be a natural consequence of clinical equipoise, that is, genuine uncertainty about the relative benefits of treatments before a trial is initiated. We review alternative methodologies that can offer more direct evidence about investigators’ beliefs, including Bayesian priors and forecasting analysis. The available evidence for optimism bias appears to be mixed, and can be assessed only where uncertainty is expressed explicitly at the trial design stage.
- 6 September 2024
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 58 (6) , 1180-1189
Delta Inflation, Optimism Bias, and Uncertainty in Clinical Trials
The phenomenon of delta inflation, in which design treatment effects tend to exceed observed treatment effects, has been documented in several therapeutic areas. Delta inflation has often been attributed to investigators’ optimism bias, or an unwarranted belief in the efficacy of new treatments. In contrast, we argue that delta inflation may be a natural consequence of clinical equipoise, that is, genuine uncertainty about the relative benefits of treatments before a trial is initiated. We review alternative methodologies that can offer more direct evidence about investigators’ beliefs, including Bayesian priors and forecasting analysis. The available evidence for optimism bias appears to be mixed, and can be assessed only where uncertainty is expressed explicitly at the trial design stage.
- 28 January 2024
- Published by Wiley in Pharmaceutical Statistics
- Vol. 23 (4) , 466-479
The flaw of averages: Bayes factors as posterior means of the likelihood ratio
As an alternative to the Frequentist p‐value, the Bayes factor (or ratio of marginal likelihoods) has been regarded as one of the primary tools for Bayesian hypothesis testing. In recent years, several researchers have begun to re‐analyze results from prominent medical journals, as well as from trials for FDA‐approved drugs, to show that Bayes factors often give divergent conclusions from those of p‐values. In this paper, we investigate the claim that Bayes factors are straightforward to interpret as directly quantifying the relative strength of evidence. In particular, we show that for nested hypotheses with consistent priors, the Bayes factor for the null over the alternative hypothesis is the posterior mean of the likelihood ratio. By re‐analyzing 39 results previously published in the New England Journal of Medicine, we demonstrate how the posterior distribution of the likelihood ratio can be computed and visualized, providing useful information beyond the posterior mean alone.
- 28 January 2024
- Published by Wiley in Pharmaceutical Statistics
- Vol. 23 (4) , 466-479
The flaw of averages: Bayes factors as posterior means of the likelihood ratio
As an alternative to the Frequentist p‐value, the Bayes factor (or ratio of marginal likelihoods) has been regarded as one of the primary tools for Bayesian hypothesis testing. In recent years, several researchers have begun to re‐analyze results from prominent medical journals, as well as from trials for FDA‐approved drugs, to show that Bayes factors often give divergent conclusions from those of p‐values. In this paper, we investigate the claim that Bayes factors are straightforward to interpret as directly quantifying the relative strength of evidence. In particular, we show that for nested hypotheses with consistent priors, the Bayes factor for the null over the alternative hypothesis is the posterior mean of the likelihood ratio. By re‐analyzing 39 results previously published in the New England Journal of Medicine, we demonstrate how the posterior distribution of the likelihood ratio can be computed and visualized, providing useful information beyond the posterior mean alone.
- 3 May 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (3) , 394-412
Epistemic uncertainty in Bayesian predictive probabilities
Bayesian predictive probabilities have become a ubiquitous tool for design and monitoring of clinical trials. The typical procedure is to average predictive probabilities over the prior or posterior distributions. In this paper, we highlight the limitations of relying solely on averaging, and propose the reporting of intervals or quantiles for the predictive probabilities. These intervals formalize the intuition that uncertainty decreases with more information. We present four different applications (Phase 1 dose escalation, early stopping for futility, sample size re-estimation, and assurance/probability of success) to demonstrate the practicality and generality of the proposed approach.
- 3 May 2023
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 34 (3) , 394-412
Epistemic uncertainty in Bayesian predictive probabilities
Bayesian predictive probabilities have become a ubiquitous tool for design and monitoring of clinical trials. The typical procedure is to average predictive probabilities over the prior or posterior distributions. In this paper, we highlight the limitations of relying solely on averaging, and propose the reporting of intervals or quantiles for the predictive probabilities. These intervals formalize the intuition that uncertainty decreases with more information. We present four different applications (Phase 1 dose escalation, early stopping for futility, sample size re-estimation, and assurance/probability of success) to demonstrate the practicality and generality of the proposed approach.
- 10 October 2022
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 123, 106957
A parallel sampling framework for model averaging: Application to dose response studies
- 10 October 2022
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 123, 106957
A parallel sampling framework for model averaging: Application to dose response studies
- 1 March 2014
- Published by Elsevier in Journal of Chromatography A
- Vol. 1333, 134-137
Rapid quantification of highly polar trimethyl phosphate in wastewater via direct analysis in real-time mass spectrometry
- 1 March 2014
- Published by Elsevier in Journal of Chromatography A
- Vol. 1333, 134-137
Rapid quantification of highly polar trimethyl phosphate in wastewater via direct analysis in real-time mass spectrometry